Find Nusinersen manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

17RELATED EXCIPIENT COMPANIES

15EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Gtpl9416, Isis396443
Molecular Formula
C234H340N61O128P17S17
Molecular Weight
7127  g/mol
InChI Key
WWFDJIVIDXJAQR-FFWSQMGZSA-N

Nusinersen
1 2D Structure

Nusinersen

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[(2R,3R,4R,5R)-4-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(4-amino-5-methyl-2-oxopyrimidin-1-yl)-3-[[(2R,3R,4R,5R)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[(2R,3R,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-sulfanylphosphoryl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(2-amino-6-oxo-1H-purin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(6-aminopurin-9-yl)-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-4-(2-methoxyethoxy)oxolan-2-yl]methoxy-hydroxyphosphinothioyl]oxy-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
2.1.2 InChI
InChI=1S/C234H340N61O128P17S17/c1-106-66-278(224(308)261-178(106)235)205-162(356-50-32-338-14)144(119(391-205)79-373-425(320,442)407-143-117(77-296)389-204(161(143)355-49-31-337-13)282-70-110(5)193(298)271-228(282)312)410-431(326,448)383-89-129-154(172(366-60-42-348-24)215(401-129)289-99-254-135-182(239)246-95-250-186(135)289)419-436(331,453)379-81-121-145(163(357-51-33-339-15)206(393-121)279-67-107(2)179(236)262-225(279)309)408-426(321,443)375-83-123-149(167(361-55-37-343-19)210(395-123)284-72-112(7)195(300)273-230(284)314)413-429(324,446)378-86-125-150(168(362-56-38-344-20)211(397-125)285-73-113(8)196(301)274-231(285)315)414-430(325,447)377-85-124-148(166(360-54-36-342-18)209(396-124)283-71-111(6)194(299)272-229(283)313)412-428(323,445)374-80-120-147(165(359-53-35-341-17)208(392-120)281-69-109(4)181(238)264-227(281)311)411-432(327,449)384-90-130-155(173(367-61-43-349-25)216(402-130)290-100-255-136-183(240)247-96-251-187(136)290)420-437(332,454)381-87-127-152(170(364-58-40-346-22)213(399-127)287-75-115(10)198(303)276-233(287)317)415-433(328,450)385-91-131-157(175(369-63-45-351-27)218(403-131)292-102-257-138-185(242)249-98-253-189(138)292)422-440(335,457)386-92-132-156(174(368-62-44-350-26)217(404-132)291-101-256-137-184(241)248-97-252-188(137)291)421-438(333,455)382-88-128-153(171(365-59-41-347-23)214(400-128)288-76-116(11)199(304)277-234(288)318)417-435(330,452)388-94-134-159(177(371-65-47-353-29)220(406-134)295-105-260-141-192(295)267-223(245)270-202(141)307)423-439(334,456)380-82-122-146(164(358-52-34-340-16)207(394-122)280-68-108(3)180(237)263-226(280)310)409-427(322,444)376-84-126-151(169(363-57-39-345-21)212(398-126)286-74-114(9)197(302)275-232(286)316)416-434(329,451)387-93-133-158(176(370-64-46-352-28)219(405-133)294-104-259-140-191(294)266-222(244)269-201(140)306)418-424(319,441)372-78-118-142(297)160(354-48-30-336-12)203(390-118)293-103-258-139-190(293)265-221(243)268-200(139)305/h66-76,95-105,117-134,142-177,203-220,296-297H,30-65,77-94H2,1-29H3,(H,319,441)(H,320,442)(H,321,443)(H,322,444)(H,323,445)(H,324,446)(H,325,447)(H,326,448)(H,327,449)(H,328,450)(H,329,451)(H,330,452)(H,331,453)(H,332,454)(H,333,455)(H,334,456)(H,335,457)(H2,235,261,308)(H2,236,262,309)(H2,237,263,310)(H2,238,264,311)(H2,239,246,250)(H2,240,247,251)(H2,241,248,252)(H2,242,249,253)(H,271,298,312)(H,272,299,313)(H,273,300,314)(H,274,301,315)(H,275,302,316)(H,276,303,317)(H,277,304,318)(H3,243,265,268,305)(H3,244,266,269,306)(H3,245,267,270,307)/t117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,155-,156-,157-,158-,159-,160-,161-,162-,163-,164-,165-,166-,167-,168-,169-,170-,171-,172-,173-,174-,175-,176-,177-,203-,204-,205-,206-,207-,208-,209-,210-,211-,212-,213-,214-,215-,216-,217-,218-,219-,220-,424?,425?,426?,427?,428?,429?,430?,431?,432?,433?,434?,435?,436?,437?,438?,439?,440?/m1/s1
2.1.3 InChI Key
WWFDJIVIDXJAQR-FFWSQMGZSA-N
2.1.4 Canonical SMILES
CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)OP(=S)(O)OCC3C(C(C(O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OCC5C(C(C(O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OCC8C(C(C(O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=O)(OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)S)OCCOC
2.1.5 Isomeric SMILES
CC1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)OP(=S)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=C(C(=NC4=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]5[C@H]([C@H]([C@@H](O5)N6C=NC7=C(N=CN=C76)N)OCCOC)OP(=S)(O)OC[C@@H]8[C@H]([C@H]([C@@H](O8)N9C=C(C(=NC9=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C(N=CN=C21)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=O)(OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)OP(=S)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C=NC2=C1N=C(NC2=O)N)OCCOC)O)S)OCCOC
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. Gtpl9416

2. Isis396443

2.3 Create Date
2017-01-30
3 Chemical and Physical Properties
Molecular Weight 7127 g/mol
Molecular Formula C234H340N61O128P17S17
XLogP3-14.4
Hydrogen Bond Donor Count40
Hydrogen Bond Acceptor Count167
Rotatable Bond Count176
Exact Mass7124.2829700 g/mol
Monoisotopic Mass7122.2762603 g/mol
Topological Polar Surface Area2820 Ų
Heavy Atom Count457
Formal Charge0
Complexity19100
Isotope Atom Count0
Defined Atom Stereocenter Count72
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 1  
Drug NameSPINRAZA
Active IngredientNUSINERSEN SODIUM
CompanyBIOGEN IDEC (Application Number: N209531. Patents: 6166197, 6210892, 7101993, 7838657, 8110560, 8361977, 8980853)

USDMF

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed

01

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43092

Submission : 2025-11-20

Status : Active

Type : II

blank

02

AACR Annual meeting
Not Confirmed

03

AACR Annual meeting
Not Confirmed

03

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41696

Submission : 2025-04-17

Status : Active

Type : II

blank

04

AACR Annual meeting
Not Confirmed

04

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41707

Submission : 2025-03-28

Status : Active

Type : II

blank

05

AACR Annual meeting
Not Confirmed

05

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 43283

Submission : 2025-12-26

Status : Active

Type : II

blank

06

Shanghai Sinuotides Biopharmaceutica...

Country

USDMF

arrow
AACR Annual meeting
Not Confirmed

06

Shanghai Sinuotides Biopharmaceutica...

Country
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 42326

Submission : 2025-08-05

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN

NDC Package Code : 71860-396

Start Marketing Date : 2016-12-23

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content

Nusinersen

About the Company : Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and a...

Transo-Pharm is a licensed distributor of pharmaceutical components for human and veterinary markets. The company supports the full API life cycle, from development to sales, and acts as a sourcing and regulatory marketing agent for API manufacturers. Transo-Pharm assists with DMF setup, GMP consulting, and regulatory activities, supported by a regulatory team, warehouse facilities, proprietary API process IPs, and laboratory partnerships, with offices in Shanghai, Hong Kong, Singapore, and the US. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Transo Pharm USA Company Banner

02

Aspen API

Netherlands
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAspen API. More than just an API™

Flag Netherlands
Digital Content Digital Content

Nusinersen

About the Company : Aspen API is a cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. The company supplies a broad portfolio of over 50 high-qual...

Aspen API is a cooperative entity formed by Aspen Oss in the Netherlands and Fine Chemicals Corporation in South Africa. The company supplies a broad portfolio of over 50 high-quality APIs, including high-potency products, oncology, peptides, narcotics, analgesics, botanical extractions, and biochemicals. Aspen API emphasizes quality, compliance, and teamwork, while integrating sustainable practices through the use of eco-friendly technologies and solvents in its manufacturing processes. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Aspen API Comapny Banner

03

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Nusinersen

About the Company : Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle manage...

Pharmathen, established in 1969, has emerged as a leading in-house development partner in Europe. It specializes in the development, registration, manufacturing & life-cycle management of complex pharmaceutical technologies & generic formulations. With a portfolio of over 100 products, Pharmathen serves over 250 clients across 80 countries. It’s pipeline includes advanced long-acting injectables, sustained-release formulations & preservative-free ophthalmics manufactured in USFDA & EU-approved facilities. Pharmathen’s core technology platforms, including microspheres, nanosuspensions & nanogels, are used to develop long-acting therapies.
Pharmathen

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Nusinersen

About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...

Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Omgene Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Nusinersen Sodium

About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...

Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios with over 350 products, alongside tailored CDMO services. Leveraging deep expertise and diverse technologies, we deliver flexible, high-quality solutions to meet our partners’ needs. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
TAPI Company Banner

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Nusinersen

About the Company : Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuz...

Anhui Ribobay Pharmaceutical Co., Ltd., known as Ribobay, was established in August 2021 as a fully owned subsidiary of General Biol. Situated in the Quanjiao industry Zone in Chuzhou, within the Nanjing metropolitan area, Ribobay Pharmaceutical specializes in the therapeutic oligonucleotides CXO field. This strategic focus aligns with General Biol's broader expansion plans for its CXO business, making Ribobay a crucial component of the company's ventures in this domain.
blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Nusinersen Sodium

About the Company : Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and effici...

Sinopep leads the industry in therapeutic peptides, supplying top-demand APIs like Albuvirtide, Lanreotide, Semaglutide, and more. Renowned for high-quality peptide APIs and efficient manufacturing technologies, Sinopep ensures global compliance with advanced process development. Their CRDMO services span peptides, oligonucleotides, and synthetic conjugates, making them a trusted partner worldwide in pharmaceutical and healthcare solutions.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Nusinersen Sodium is a oligonucleotide drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of muscular atrophy, spinal.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 30, 2026

blank

01

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Nusinersen Sodium is a oligonucleotide drug, which is currently being evaluated in Approved FDF clinical studies for the treatment of muscular atrophy, spinal.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

March 30, 2026

blank

Details:

Nusinersen Sodium, an oligonucleotide targeting SMN2 pre-mRNA, shows promise in treating 5q spinal muscular atrophy (SMA).


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 12, 2026

blank

02

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Nusinersen Sodium, an oligonucleotide targeting SMN2 pre-mRNA, shows promise in treating 5q spinal muscular atrophy (SMA).

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

January 12, 2026

blank

Details:

Apitegromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Muscular Atrophy, Spinal.


Lead Product(s): Apitegromab,Nusinersen,Risdiplam

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Antibody, Unconjugated

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 02, 2025

blank

03

Scholar Rock

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Scholar Rock

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Apitegromab is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Muscular Atrophy, Spinal.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

July 02, 2025

blank

Details:

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 23, 2025

blank

04

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

January 23, 2025

blank

Details:

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 09, 2024

blank

05

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and Toddlers.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

October 09, 2024

blank

Details:

Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Phase II/ Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 04, 2024

blank

06

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide investigated for the treatment of spinal muscular atrophy (SMA) in pediatrics.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

September 04, 2024

blank

Details:

Nusinersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Atrophy, Spinal.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 15, 2024

blank

07

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Nusinersen is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Muscular Atrophy, Spinal.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

August 15, 2024

blank

Details:

Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Lantesens

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 14, 2024

blank

08

Generium

Russia
arrow
AACR Annual meeting
Not Confirmed

Generium

Russia
arrow
AACR Annual meeting
Not Confirmed

Details : Lantesens (nusinersen) is a generic of Spinraza, which is SMN2-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Product Name : Lantesens

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

May 14, 2024

blank

Details:

Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 06, 2024

blank

09

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Details : Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

March 06, 2024

blank

Details:

SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.


Lead Product(s): Nusinersen,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Spinraza

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Biogen

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 27, 2023

blank

10

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : SPINRAZA (nusinersen) is an antisense oligonucleotide (ASO) that targets the root cause of SMA by continuously increasing the amount of full-length survival motor neuron (SMN) protein produced in the body.

Product Name : Spinraza

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

June 27, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Regulatory Info : USA

Registration Country : Greece

Nusinersen

Brand Name :

Dosage Form : Solution For Injection

Dosage Strength : 12MG/5ML

Packaging :

Approval Date :

Application Number :

Regulatory Info : USA

Registration Country : Greece

Pharmathen

02

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN SODIUM

Brand Name : SPINRAZA

Dosage Form : SOLUTION;INTRATHECAL

Dosage Strength : EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)

Packaging :

Approval Date : 2016-12-23

Application Number : 209531

Regulatory Info : RX

Registration Country : USA

blank

03

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form : Solution For Injection

Dosage Strength : 12mg/5ml

Packaging :

Approval Date : 20/09/2017

Application Number : 66495

Regulatory Info : Allowed

Registration Country : Switzerland

blank

04

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form : Solution For Injection

Dosage Strength : 12mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

05

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form : Solution For Injection

Dosage Strength : 24mg/ml

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

06

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form : Injectable Solution

Dosage Strength : 12MG

Packaging :

Approval Date : 06-07-2017

Application Number : 1171188001

Regulatory Info : Authorized

Registration Country : Spain

blank

07

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form : Injection Solution

Dosage Strength : 2.4mg/ml

Packaging :

Approval Date : 30-05-2017

Application Number : 28105860816

Regulatory Info : Prescription

Registration Country : Denmark

blank

08

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Nusinersen Sodium

Brand Name : Spinraza

Dosage Form : Injectable Solution

Dosage Strength : 12mg

Packaging :

Approval Date : 30-05-2017

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

09

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

NUSINERSEN (NUSINERSEN SODIUM)

Brand Name : SPINRAZA

Dosage Form : SOLUTION

Dosage Strength : 2.4MG/ML

Packaging : 5ML

Approval Date :

Application Number : 2465663

Regulatory Info : PRESCRIPTION

Registration Country : Canada

blank

10

Biogen

U.S.A
AACR Annual meeting
Not Confirmed
arrow

Biogen

U.S.A
arrow
AACR Annual meeting
Not Confirmed

Nusinersen

Brand Name : Spinraza

Dosage Form :

Dosage Strength :

Packaging : 1

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Australia

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

API Stability Enhancers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for / Nusinersen API manufacturers, exporters & distributors?

Nusinersen manufacturers, exporters & distributors 1

62

PharmaCompass offers a list of Nusinersen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nusinersen manufacturer or Nusinersen supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Nusinersen manufacturer or Nusinersen supplier.

API | Excipient name

Nusinersen

Synonyms

Gtpl9416, Isis396443

Nusinersen Manufacturers

A Nusinersen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nusinersen, including repackagers and relabelers. The FDA regulates Nusinersen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nusinersen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Nusinersen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Nusinersen Suppliers

A Nusinersen supplier is an individual or a company that provides Nusinersen active pharmaceutical ingredient (API) or Nusinersen finished formulations upon request. The Nusinersen suppliers may include Nusinersen API manufacturers, exporters, distributors and traders.

click here to find a list of Nusinersen suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Nusinersen USDMF

A Nusinersen DMF (Drug Master File) is a document detailing the whole manufacturing process of Nusinersen active pharmaceutical ingredient (API) in detail. Different forms of Nusinersen DMFs exist exist since differing nations have different regulations, such as Nusinersen USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Nusinersen DMF submitted to regulatory agencies in the US is known as a USDMF. Nusinersen USDMF includes data on Nusinersen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Nusinersen USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Nusinersen suppliers with USDMF on PharmaCompass.

Nusinersen NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Nusinersen as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Nusinersen API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Nusinersen as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Nusinersen and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Nusinersen NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Nusinersen suppliers with NDC on PharmaCompass.

Nusinersen GMP

Nusinersen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Nusinersen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Nusinersen GMP manufacturer or Nusinersen GMP API supplier for your needs.

Nusinersen CoA

A Nusinersen CoA (Certificate of Analysis) is a formal document that attests to Nusinersen's compliance with Nusinersen specifications and serves as a tool for batch-level quality control.

Nusinersen CoA mostly includes findings from lab analyses of a specific batch. For each Nusinersen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Nusinersen may be tested according to a variety of international standards, such as European Pharmacopoeia (Nusinersen EP), Nusinersen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nusinersen USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty